Mounjaro now licenced for weight loss in the UK
The UK medicines agency has just licenced Mounjaro for weight loss treatments. Described as the “King Kong” of weight loss drugs, Mounjaro is the most effective medication available giving average weight loss of over 25% in 18 months.
The MHRA's decision
The Medicines and Healthcare products Regulatory Agency (MHRA) has granted a licence for Mounjaro for weight loss in adults aged 18. Until now it had only been licenced for people with type 2 diabetes. Although the manufacturer, Eli Lilly, has not given a launch date, it is likely to come within the next few months, hopefully in early 2024.
CheqUp will be offering Mounjaro as soon as it becomes available - please watch our website for updates.
Mounjaro (with the active drug tirzepatide) has been described as the “King Kong” of weight loss drugs as the most recent SURMOUNT clinical trials indicate average weight loss of over 25% in 18 months of taking the drug. This significantly exceeds the weight loss recorded for Wegovy - 15% in 68 weeks.
Who can use Mounjaro?
Mounjaro is authorised for adult patients who fall into two categories:
- 1. Those with a BMI of 30kg/m² or more (considered obese).
- 2. Individuals with a BMI between 27-30kg/m² (overweight) who also have weight-related health issues such as prediabetes, high blood pressure, high cholesterol, or heart problems.
This ground-breaking medicine is designed to be used in combination with a reduced-calorie diet and increased physical activity of the kind offered by CheqUp. It is not recommended to take this class of drug without professional support given the side-effects, problems through the dose increase stage, and the difficulties which many people find in using the injection pens.
How does Mounjaro work?
Dosage and administration
The MHRA’s swift assessment
Published: 09 Nov 2023